Yahoo Finance18d
Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan
Setmelanotide is a melanocortin-4 receptor (MC4R) agonist designed to treat hyperphagia and obesity. Rhythm is evaluating setmelanotide in a global Phase 3 trial in patients with acquired ...
Rhythm Pharmaceuticals Announces Orphan Drug Designation Granted to Setmelanotide for Treatment of Hypothalamic Obesity in Japan
Setmelanotide is a melanocortin-4 receptor (MC4R) agonist designed to treat hyperphagia and obesity. Rhythm is evaluating setmelanotide in a global Phase 3 trial in patients with acquired hypothalamic ...
Pharmabiz16d
Rhythm Pharma gets orphan drug designation for its setmelanotide to treat hypothalamic obesity in Japan
Setmelanotide is a melanocortin-4 receptor (MC4R) agonist designed to treat hyperphagia and obesity. Rhythm is evaluating setmelanotide in a global phase 3 trial in patients with acquired hypothalamic ...
Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.
Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the ...
Yahoo Finance17d
Rhythm Pharmaceuticals Reacquires Licensing Rights to IMCIVREE® (setmelanotide) in China with Termination of Agreement with RareStone Ltd.
“Our global trial of setmelanotide in patients with acquired hypothalamic obesity – which is on track for topline data readout in the second quarter of 2025 – is being conducted in North ...
Nasdaq18d
Rhythm Pharmaceuticals Receives Orphan Drug Designation in Japan for Setmelanotide in Acquired Hypothalamic Obesity Treatment
Rhythm Pharmaceuticals, Inc. has announced that it received orphan drug designation from Japan's Ministry of Health, Labour and Welfare for setmelanotide, a treatment aimed at acquired ...